ATE514091T1 - Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit - Google Patents

Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit

Info

Publication number: ATE514091T1
Authority: AT; Austria
Prior art keywords: procalcitonin; prognosis; pct; infectious disease; patients
Prior art date: 2007-08-03

Application number

AT08786791T

Other languages

English (en)

Inventor

Joachim Struck

Andreas Bergmann

Original Assignee

Brahms Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-03

Filing date

2008-08-01

Publication date

2011-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39745280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE514091(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-08-03 Priority claimed from EP07015271A external-priority patent/EP2020603A1/de

2008-03-12 Priority claimed from EP08152651A external-priority patent/EP2101178A1/de

2008-08-01 Application filed by Brahms Gmbh filed Critical Brahms Gmbh

2011-07-15 Application granted granted Critical

2011-07-15 Publication of ATE514091T1 publication Critical patent/ATE514091T1/de

Links

108010048233 Procalcitonin Proteins 0.000 title abstract 4
CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 title abstract 4
208000031662 Noncommunicable disease Diseases 0.000 title abstract 2
238000004393 prognosis Methods 0.000 title abstract 2
238000013517 stratification Methods 0.000 title abstract 2
238000000338 in vitro Methods 0.000 abstract 2
238000003556 assay Methods 0.000 abstract 1
210000001124 body fluid Anatomy 0.000 abstract 1
239000010839 body fluid Substances 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Pathology (AREA)
Microbiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT08786791T 2007-08-03 2008-08-01 Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit ATE514091T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP07015271A EP2020603A1 (de)	2007-08-03	2007-08-03	Verfahren zur Einteilung von Risikoklassen bei stabiler Erkrankung der Koronaraterien
EP08152651A EP2101178A1 (de)	2008-03-12	2008-03-12	Verwendung von Procalcitonin zur Prognose folgender akuter Koronarsyndromen
PCT/EP2008/060176 WO2009019230A2 (en)	2007-08-03	2008-08-01	Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease

Publications (1)

Publication Number	Publication Date
ATE514091T1 true ATE514091T1 (de)	2011-07-15

Family

ID=39745280

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT10188288T ATE533061T1 (de)	2007-08-03	2008-08-01	Verfahren zur diagnose bakterieller infektionen
AT08786791T ATE514091T1 (de)	2007-08-03	2008-08-01	Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT10188288T ATE533061T1 (de)	2007-08-03	2008-08-01	Verfahren zur diagnose bakterieller infektionen

Country Status (8)

Country	Link
US (3)	US20110136161A1 (de)
EP (4)	EP2293078B1 (de)
JP (2)	JP5059943B2 (de)
CN (3)	CN110346577A (de)
AT (2)	ATE533061T1 (de)
DE (1)	DE602008021800C5 (de)
ES (3)	ES2401703T3 (de)
WO (1)	WO2009019230A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2293078B1 (de)	2007-08-03	2011-11-09	B.R.A.H.M.S GmbH	Verfahren zur Diagnose bakterieller Infektionen
PT2419741T (pt) *	2009-04-14	2019-11-04	Brahms Gmbh	Avaliação de risco para tratamento com antibióticos em pacientes que sofrem de doença não infeciosa primária através da determinação do nível de procalcitonina
JP5731489B2 (ja) *	2009-06-05	2015-06-10	ベー．エル．アー．ハー．エム．エスゲゼルシャフトミットベシュレンクテルハフツング	呼吸困難を起こした患者における細菌感染の検出
EP2470910B1 (de)	2009-08-28	2017-01-11	B.R.A.H.M.S GmbH	Procalcitonin zur Prognose von Nebenwirkungen
ES2601104T3 (es)	2009-10-13	2017-02-14	B.R.A.H.M.S Gmbh	Procalcitonina para el diagnóstico de infecciones bacterianas y la guía del tratamiento antibiótico en pacientes con apoplejía aguda o accidente isquémico transitorio
WO2011110565A1 (en) *	2010-03-08	2011-09-15	B.R.A.H.M.S Gmbh	Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints
ITRM20100121A1 (it) *	2010-03-18	2011-09-19	Univ Pisa	Marcatori molecolari per infezioni delle vie urinarie.
EP2583103B1 (de) *	2010-06-18	2016-04-20	B.R.A.H.M.S GmbH	Biomarker zur Vorhersage der Inzidenz von Krebs
US20130024205A1 (en) *	2011-07-18	2013-01-24	International Business Machines Corporation	Dynamically updating electronic medical records and leveraging a person's path in a facility to mitgate risks
CA2863819C (en)	2012-02-09	2021-11-23	Memed Diagnostics Ltd.	Signatures and determinants for diagnosing infections and methods of use thereof
IN2014MN02101A (de) *	2012-04-12	2015-08-28	Brahms Gmbh
MX357740B (es)	2012-05-18	2018-07-23	Critical Care Diagnostics Inc	Métodos para determinar el pronóstico del tratamiento de un sujeto con un desfibrilador cardíaco implantado, un dispositivo de tratamiento de resincronización cardíaca o un dispositivo combinado de desfibrilador cardíaco implantado y de resincronización cardíaca.
CA2882133A1 (en)	2012-08-16	2014-02-20	Critical Care Diagnostics, Inc.	Methods for predicting risk of developing hypertension
IN2015DN04062A (de)	2012-11-15	2015-10-09	Ortho Clinical Diagnostics Inc
CN111624346A (zh)	2014-08-14	2020-09-04	米密德诊断学有限公司	用于预测及/或决定预后的套组
US20170234873A1 (en)	2014-10-14	2017-08-17	Memed Diagnostics Ltd.	Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
CA2968650A1 (en)	2014-12-11	2016-06-16	Memed Diagnostics Ltd.	Marker combinations for diagnosing infections and methods of use thereof
CA3012985A1 (en)	2015-01-27	2016-08-04	Kardiatonos, Inc.	Biomarkers of vascular disease
US20180224464A1 (en) *	2015-06-09	2018-08-09	Osaka University	Method of predicting and determining therapeutic effect on rheumatoid arthritis due to biological formulation
WO2017149547A1 (en)	2016-03-03	2017-09-08	Memed Diagnostics Ltd.	Analyzing rna for diagnosing infection type
US11466331B2 (en)	2016-03-03	2022-10-11	Memed Diagnostics Ltd.	RNA determinants for distinguishing between bacterial and viral infections
CN106093416B (zh) *	2016-05-18	2018-10-12	北京北方生物技术研究所有限公司	一种一步法检测降钙素原的试剂盒及其制备方法
WO2018011796A1 (en)	2016-07-10	2018-01-18	Memed Diagnostics Ltd.	Early diagnosis of infections
CA3027341A1 (en)	2016-07-10	2018-01-18	Memed Diagnostics Ltd.	Protein signatures for distinguishing between bacterial and viral infections
EP3519834A4 (de)	2016-09-29	2020-06-17	MeMed Diagnostics Ltd.	Verfahren zur risikobewertung und krankheitsklassifizierung
EP3519833B1 (de)	2016-09-29	2024-08-14	MeMed Diagnostics Ltd.	Verfahren zur prognose und behandlung
CN111094981B (zh) *	2017-09-13	2024-04-16	B.R.A.H.M.S有限公司	Pct和pro-adm作为监测抗生素治疗的标记物
CN111656189A (zh) *	2017-12-20	2020-09-11	B.R.A.H.M.S有限公司	基于合并症患者的降钙素原的抗生素疗法指导
US12322100B2 (en)	2018-12-11	2025-06-03	Eko.Ai Pte. Ltd.	Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US11931207B2 (en)	2018-12-11	2024-03-19	Eko.Ai Pte. Ltd.	Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en)	2018-12-11	2022-09-20	Eko.Ai Pte. Ltd.	Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en)	2018-12-11	2024-06-04	Eko.Ai Pte. Ltd.	Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12400762B2 (en)	2018-12-11	2025-08-26	Eko.Ai Pte. Ltd.	Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
WO2022119593A1 (en) *	2020-12-02	2022-06-09	Beckman Coulter, Inc.	Detection of probability of developing sepsis
US20240221958A1 (en)	2021-04-30	2024-07-04	Roche Diagnostics Operations, Inc.	Pct marker panels for early detection of sepsis
JP2024516677A (ja)	2021-04-30	2024-04-16	エフ．ホフマン－ラロシュアーゲー	敗血症の早期検出用のｎｇａｌマーカーパネル
WO2022229416A2 (en)	2021-04-30	2022-11-03	Roche Diagnostics Gmbh	Esm1 marker panels for early detection of sepsis
WO2022229440A2 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Sflt1 marker panels for early detection of sepsis
CN117242350A (zh)	2021-04-30	2023-12-15	豪夫迈·罗氏有限公司	用于脓毒症的早期检测的il6标志物组
US20240230673A1 (en)	2021-04-30	2024-07-11	Roche Diagnostics Operations, Inc.	Gdf15 marker panels for early detection of sepsis
WO2022229421A2 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Strem1 marker panels for early detection of sepsis
JP2024516679A (ja)	2021-04-30	2024-04-16	エフ．ホフマン－ラロシュアーゲー	敗血症の早期検出用のｉｇｆｂｐ７マーカーパネル
CN117321419A (zh)	2021-04-30	2023-12-29	豪夫迈·罗氏有限公司	用于脓毒症的早期检测的Presepsin标志物组
JP2024537774A (ja)	2021-09-29	2024-10-16	エフ．ホフマン－ラロシュアーゲー	敗血症の早期検出のためのＭＲ－ｐｒｏＡＤＭマーカーパネル
CN118742814A (zh)	2022-02-21	2024-10-01	豪夫迈·罗氏有限公司	用于脓毒症的早期检测的dll1标志物组
EP4357778A1 (de)	2022-10-20	2024-04-24	Heraeus Medical GmbH	Behandlung von mikrobiellen infektionen mit diagnose durch biomarker d-lactat
CN119306832B (zh) *	2023-07-11	2025-08-08	东莞市朋志生物科技有限公司	抗降钙素原抗体、检测降钙素原的试剂和试剂盒

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4227454C1 (de)	1992-08-19	1994-02-03	Henning Berlin Gmbh	Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US6147688A (en)	1993-06-28	2000-11-14	Athena Design Systems, Inc.	Method and apparatus for defining and selectively repeating unit image cells
US5795725A (en)	1995-04-18	1998-08-18	Biosite Diagnostics Incorporated	Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
DE19600875C1 (de) *	1996-01-12	1997-06-26	Brahms Diagnostica Gmbh	Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse
US6156521A (en)	1997-12-19	2000-12-05	Biosite Diagnostics, Inc.	Methods for the recovery and measurement of troponin complexes
US5993811A (en) *	1997-02-03	1999-11-30	Biology Associates, Llc	Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
US5947124A (en)	1997-03-11	1999-09-07	Biosite Diagnostics Incorporated	Diagnostic for determining the time of a heart attack
DE19903336C2 (de)	1999-01-28	2000-12-14	Brahms Diagnostica Gmbh	Gebrauchsfertige Kalibratoren für die Bestimmung von Procalcitonin
US20040253637A1 (en) *	2001-04-13	2004-12-16	Biosite Incorporated	Markers for differential diagnosis and methods of use thereof
US7713705B2 (en) *	2002-12-24	2010-05-11	Biosite, Inc.	Markers for differential diagnosis and methods of use thereof
US7632647B2 (en)	2001-04-13	2009-12-15	Biosite Incorporated	Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
DE60233301D1 (de) *	2001-05-04	2009-09-24	Biosite Inc	Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
AU2003302340B8 (en)	2002-12-24	2008-09-11	Biosite Incorporated	Markers for differential diagnosis and methods of use thereof
DE10316583A1 (de) *	2003-04-10	2004-10-28	B.R.A.H.M.S Aktiengesellschaft	Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
EP1616181B1 (de)	2003-04-17	2009-08-12	Vermillion, Inc.	Mit natriuretischen peptiden verwandte polypeptide und verfahren zu ihrer identifizierung und verwendung
US20050148029A1 (en)	2003-09-29	2005-07-07	Biosite, Inc.	Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
WO2005035720A2 (en) *	2003-10-03	2005-04-21	Scantibodies Laboratory, Inc.	Methods and use of binding components for improving assay specificity
CA2485722A1 (en)	2003-10-22	2005-04-22	Paul Lehmann	Soluble transferrin receptor
EP1564558B1 (de)	2004-02-13	2005-12-07	B.R.A.H.M.S Aktiengesellschaft	Verfahren zur Bestimmung der Bildung von Endothelinen zu Zwecken der medizinischen Diagnostik, sowie Antikörper und Kits für die Durchführung eines solchen Verfahrens
US20060024744A1 (en)	2004-07-28	2006-02-02	Mills Rhonda A	Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte
DE102004041659A1 (de)	2004-08-27	2006-03-02	Institut Virion/Serion Gmbh	Testvorrichtung für die in vitro Diagnostik von Multianalyt-Tests und deren Verwendung
AU2006264175B2 (en)	2005-06-28	2012-01-12	Nowdiagnostics, Inc.	Membrane array and analytical device
DE102005034174A1 (de) *	2005-07-21	2007-02-08	B.R.A.H.M.S Ag	Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen
JP2009510478A (ja) *	2005-10-03	2009-03-12	バイオサイトインコーポレイテッド	全身性炎症反応症候群の診断および／または予後診断のための方法および組成物
CN1800384A (zh) *	2005-11-08	2006-07-12	浙江大学	降钙素原的制备方法
EP2005168A4 (de)	2006-03-09	2009-05-20	Biosite Inc	Verfahren und zusammensetzung zur diagnose von krankheiten der aorta
DE102006046996A1 (de)	2006-10-01	2008-04-03	Brahms Aktiengesellschaft	Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
EP2020603A1 (de)	2007-08-03	2009-02-04	BRAHMS Aktiengesellschaft	Verfahren zur Einteilung von Risikoklassen bei stabiler Erkrankung der Koronaraterien
EP2293078B1 (de) *	2007-08-03	2011-11-09	B.R.A.H.M.S GmbH	Verfahren zur Diagnose bakterieller Infektionen
DE102008037108A1 (de)	2008-08-08	2010-02-11	Samson Aktiengesellschaft	System zum Stellen eines Stellorgans
ES2601104T3 (es) *	2009-10-13	2017-02-14	B.R.A.H.M.S Gmbh	Procalcitonina para el diagnóstico de infecciones bacterianas y la guía del tratamiento antibiótico en pacientes con apoplejía aguda o accidente isquémico transitorio
US20110263438A1 (en)	2010-04-22	2011-10-27	Mehmet Ali Soylemez	Diagnosis and complication risk assessment of pancreatic diabetes using procalcitonin

2008
- 2008-08-01 EP EP10188288A patent/EP2293078B1/de active Active
- 2008-08-01 AT AT10188288T patent/ATE533061T1/de active
- 2008-08-01 US US12/671,702 patent/US20110136161A1/en not_active Abandoned
- 2008-08-01 JP JP2010518695A patent/JP5059943B2/ja active Active
- 2008-08-01 DE DE602008021800.7A patent/DE602008021800C5/de active Active
- 2008-08-01 ES ES10188289T patent/ES2401703T3/es active Active
- 2008-08-01 WO PCT/EP2008/060176 patent/WO2009019230A2/en not_active Ceased
- 2008-08-01 CN CN201910283751.1A patent/CN110346577A/zh active Pending
- 2008-08-01 CN CN201210451017.XA patent/CN103123359B/zh active Active
- 2008-08-01 ES ES10188288T patent/ES2377112T3/es active Active
- 2008-08-01 EP EP10188287A patent/EP2301626B1/de active Active
- 2008-08-01 ES ES10188287T patent/ES2403310T3/es active Active
- 2008-08-01 CN CN200880101846A patent/CN101790687A/zh active Pending
- 2008-08-01 EP EP10188289A patent/EP2293076B1/de active Active
- 2008-08-01 AT AT08786791T patent/ATE514091T1/de active
- 2008-08-01 EP EP08786791A patent/EP2174143B1/de active Active
2011
- 2011-02-25 US US13/034,752 patent/US10456364B2/en active Active
2012
- 2012-08-02 JP JP2012171897A patent/JP5185460B2/ja active Active
2019
- 2019-03-29 US US16/369,966 patent/US11241395B2/en active Active

Also Published As

Publication number	Publication date
EP2293076A2 (de)	2011-03-09
CN103123359A (zh)	2013-05-29
WO2009019230A3 (en)	2009-04-23
JP2012237760A (ja)	2012-12-06
CN103123359B (zh)	2015-07-29
US20110152170A1 (en)	2011-06-23
US20190224135A1 (en)	2019-07-25
JP5059943B2 (ja)	2012-10-31
US11241395B2 (en)	2022-02-08
WO2009019230A4 (en)	2009-06-25
EP2301626A3 (de)	2011-11-16
DE602008021800C5 (de)	2022-05-05
ES2403310T3 (es)	2013-05-17
CN110346577A (zh)	2019-10-18
EP2293076B1 (de)	2012-12-19
JP5185460B2 (ja)	2013-04-17
HK1183707A1 (en)	2014-01-03
JP2010536012A (ja)	2010-11-25
EP2293076A3 (de)	2011-03-30
EP2174143B1 (de)	2011-06-22
EP2293078B1 (de)	2011-11-09
US20110136161A1 (en)	2011-06-09
WO2009019230A2 (en)	2009-02-12
EP2301626B1 (de)	2013-01-16
ATE533061T1 (de)	2011-11-15
EP2293078A3 (de)	2011-04-06
ES2401703T3 (es)	2013-04-23
US10456364B2 (en)	2019-10-29
EP2174143A2 (de)	2010-04-14
ES2377112T3 (es)	2012-03-22
EP2301626A2 (de)	2011-03-30
CN101790687A (zh)	2010-07-28
EP2293078A2 (de)	2011-03-09

Legal Events

Date

Code

Title

Description

2012-01-15

UEP

Publication of translation of european patent specification

Ref document number: 2174143

Country of ref document: EP

Publication	Publication Date	Title
ATE514091T1 (de)	2011-07-15	Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit
CY1122973T1 (el)	2021-10-29	Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης
DE602006019262D1 (de)	2011-02-10	QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
EA200900177A1 (ru)	2009-06-30	Замещенные ациланилиды и способы их применения
ATE554395T1 (de)	2012-05-15	Diagnose septischer komplikationen
DE602006011896D1 (de)	2010-03-11	Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
BRPI0906683B8 (pt)	2021-07-27	método para medir e caracterizar microvesículas em fluidos corporais humanos
BR112012012610A2 (pt)	2019-09-24	terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
BRPI1011564A8 (pt)	2017-10-03	Fio de material de sutura cirúrgica, kit cirúrgico e método para produzir fio
NO20091630L (no)	2009-07-03	CCR2-antagonister for behandling av fibrose
MX2009005941A (es)	2009-07-24	Ensayos de diagnostico complementario para terapia de cancer.
EP4177234A4 (de)	2024-08-28	Kalzinierter zirkonoxidkörper zur zahnärztlichen verwendung
AR088244A1 (es)	2014-05-21	oxMIF COMO MARCADOR DE DIAGNOSTICO
MX2011008439A (es)	2011-09-06	Biomarcadores de proteina para el diagnostico de enfermedades de tejido blando y como objetivos terapeuticos para intervenciones de cuidado bucal.
WO2007109733A3 (en)	2008-01-24	Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
EP1937831A4 (de)	2009-03-18	Verwendung von n-myristoyltransferase auf nichttumorgewebe zur krebsdiagnose
MX2012005388A (es)	2012-07-23	Reactivos y metodos para detectar globulos blancos pnh tipo ii y su identificacion como factores de riesgo para transtornos trombolicos.
EP2614792A3 (de)	2016-04-06	Medizinische Membrane, insbesondere zahnmedizinische Membrane sowie Zahnimplantat mit einer solchen Membrane
CY1111602T1 (el)	2015-10-07	ΜΕΘΟΔΟΣ ΓΙΑ ΤΗΝ ΑΝΙΧΝΕΥΣΗ ΤΗΣ ΔΡΑΣΤΙΚΟΤΗΤΑΣ IN VIVO ΤΗΣ ΝΕΥΡΟΤΡΥΨΙΝΗΣ, ΧΡΗΣΗ ΤΗΣ ΜΕΘΟΔΟΥ ΚΑΙ ΧΡΗΣΗ TOY C-ΤΕΡΜΑΤΙΚΟΥ 22-kDa ΘΡΑΥΣΜΑΤΟΣ ΤΗΣ ΑΓΡΙΝΗΣ ΩΣ ΒΙΟΔΕΙΚΤΗ ΕΙΣ ΤΗΝ ΔΙΑΓΝΩΣΗ ΚΑΙ ΠΑΡΑΚΟΛΟΥΘΗΣΗ ΔΙΑΤΑΡΑΧΩΝ ΠΟΥ ΕΧΟΥΝ ΣΧΕΣΗ ΜΕ ΝΕΥΡΟΤΡΥΨΙΝΗ
BRPI0807775A2 (pt)	2014-06-24	Preparação de fluidos biológicos viralmente inativados tendo atividade de alfa-2-antiplasmina alta
WO2012075222A3 (en)	2014-04-10	Method of identifying when a patient undergoing hemodialysis is at increased risk of death
FR2917172B1 (fr)	2014-01-03	Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation
ATE522815T1 (de)	2011-09-15	Mittel und verfahren zur prognose von nierenversagen bei diabetikern auf basis des plazentalen wachstumsfaktors und löslichem flt-1
BR112013015394A2 (pt)	2016-09-20	método de determinar a presença ou a ausência, em uma amostra biológica de um paciente, de células de câncer de bexiga ou próstata, composto, e, uso de um composto
TARAR et al.	2010	ACUTE PANCREATITIS: EVALUATION OF MODIFIED GLASGOW SCORING SYSTEM (IMRIE)